{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:58:36Z","timestamp":1792047516797,"version":"4.4.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annemergmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Emergency Medicine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.annemergmed.2020.08.009","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:14:07Z","timestamp":1599869647000},"page":"S28-S36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":161,"special_numbering":"S","title":["Trends in Sickle Cell Disease\u2013Related Mortality in the United States, 1979 to 2017"],"prefix":"10.1016","volume":"76","author":[{"given":"Amanda B.","family":"Payne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason M.","family":"Mehal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Chapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana L.","family":"Haberling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa C.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Bean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Craig","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annemergmed.2020.08.009_bib1","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the US","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib2","first-page":"288","article-title":"Cerebrovascular accidents in sickle cell disease: rates and risk factors","volume":"91","author":"Ohene-Frempong","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib3","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1182\/blood-2009-05-220921","article-title":"Sickle cell disease and stroke","volume":"114","author":"Verduzco","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJM199107043250103","article-title":"Pain in sickle cell disease. Rates and risk factors","volume":"325","author":"Platt","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079923","article-title":"Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study","volume":"8","author":"Darbari","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib6","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1056\/NEJM196605052741806","article-title":"Pneumococcal meningitis in sickle-cell anemia","volume":"274","author":"Robinson","year":"1966","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00005792-197103000-00002","article-title":"Bacterial infection and sickle cell anemia. An analysis of 250 infections in 166 patients and a review of the literature","volume":"50","author":"Barrett-Connor","year":"1971","journal-title":"Medicine"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S0022-3476(86)80216-5","article-title":"Bacteremia in sickle hemoglobinopathies","volume":"109","author":"Zarkowsky","year":"1986","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib9","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1182\/blood.V86.2.776.bloodjournal862776","article-title":"Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease","volume":"86","author":"Gill","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.V84.2.643.643","article-title":"The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease","volume":"84","author":"Castro","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00408-012-9435-3","article-title":"Mortality, asthma, smoking and acute chest syndrome in young adults with sickle cell disease","volume":"191","author":"Knight-Madden","year":"2013","journal-title":"Lung"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00005792-198801000-00005","article-title":"Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure","volume":"67","author":"Powars","year":"1988","journal-title":"Medicine"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib13","doi-asserted-by":"crossref","first-page":"614","DOI":"10.7326\/0003-4819-115-8-614","article-title":"Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality","volume":"115","author":"Powars","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archinte.1990.00390150015003","article-title":"Renal abnormalities in sickle cell disease","volume":"150","author":"Allon","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib15","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1056\/NEJM199204023261402","article-title":"Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme","volume":"326","author":"Falk","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib16","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/ajh.20685","article-title":"Circumstances of death in adult sickle cell disease patients","volume":"81","author":"Darbari","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib17","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.2105\/AJPH.87.8.1317","article-title":"National trends in the mortality of children with sickle cell disease, 1968 through 1992","volume":"87","author":"Davis","year":"1997","journal-title":"Am J Public Health"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib18","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/ajh.23683","article-title":"Factors associated with survival in a contemporary adult sickle cell disease cohort","volume":"89","author":"Elmariah","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib19","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/ajh.21569","article-title":"Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease","volume":"85","author":"Fitzhugh","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib20","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/pbc.24557","article-title":"Sickle cell disease related mortality in the United States (1999-2009)","volume":"60","author":"Hamideh","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib21","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1542\/peds.84.3.500","article-title":"Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease","volume":"84","author":"Leikin","year":"1989","journal-title":"Pediatrics"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib22","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1046\/j.1365-2141.2003.04594.x","article-title":"Causes of death in sickle cell disease: an autopsy study","volume":"123","author":"Manci","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib23","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib24","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1182\/blood-2003-11-3758","article-title":"Survival of children with sickle cell disease","volume":"103","author":"Quinn","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib25","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jpeds.2008.09.052","article-title":"Trends in pediatric sickle cell disease\u2013related mortality in the United States, 1983-2002","volume":"154","author":"Yanni","year":"2009","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: US, 1979-2005","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Rep"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ajh.24235","article-title":"Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: the last 40 years","volume":"91","author":"Chaturvedi","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib29","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1056\/NEJM198606193142501","article-title":"Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial","volume":"314","author":"Gaston","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib30","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-3476(95)70154-0","article-title":"Discontinuing penicillin prophylaxis in children with sickle cell anemia. Prophylactic Penicillin Study II","volume":"127","author":"Falletta","year":"1995","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib31","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1542\/peds.81.6.749","article-title":"Newborn screening for sickle cell disease: effect on mortality","volume":"81","author":"Vichinsky","year":"1988","journal-title":"Pediatrics"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM199807023390102","article-title":"Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography","volume":"339","author":"Adams","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib33","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1067\/S0022-3476(03)00331-7","article-title":"Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination","volume":"143","author":"Adamkiewicz","year":"2003","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib34","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1097\/INF.0b013e3182a11808","article-title":"Invasive pneumococcal disease among children with and without sickle cell disease in the United States, 1998 to 2009","volume":"32","author":"Payne","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib35","first-page":"816","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"61","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib36","first-page":"527","article-title":"Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013","volume":"63","author":"MacNeil","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib37","first-page":"1","article-title":"Prevention and control of Haemophilus influenzae type b disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Briere","year":"2014","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib38","first-page":"108","volume":"63","author":"Akinsanya-Beysolow","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib39","first-page":"110","volume":"63","author":"Bridges","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib40","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2012-03-419879","article-title":"Impact of hydroxyurea on clinical events in the BABY HUG trial","volume":"120","author":"Thornburg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib41","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/pbc.24100","article-title":"Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia","volume":"59","author":"Alvarez","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib42","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib43","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood.V79.10.2555.2555","article-title":"Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia","volume":"79","author":"Charache","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib44","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib45","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00005792-199611000-00002","article-title":"Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive \"switching\" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia","volume":"75","author":"Charache","year":"1996","journal-title":"Medicine"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib46","first-page":"1550","article-title":"Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I\/II trial. Pediatric Hydroxyurea Group","volume":"94","author":"Kinney","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib47","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib48","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib49","series-title":"Vital Statistics Mortality Data, Multiple Cause Detail, 1979-2017. Public Use Data Tape Contents and Documentation Package","year":"2019"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib50","series-title":"Manual of the International Statistical Classification of Diseases, Injuries, and Causes of Death, Based on Recommendations of the Ninth Revision Conference, 1975","year":"1977"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib51","series-title":"International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)","year":"1992"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib52","first-page":"1","article-title":"Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates","volume":"49","author":"Anderson","year":"2001","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib53","series-title":"Intercensal Estimates of Population of Counties by Age, Sex and Race: 1970-1979","year":"1984"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib54","series-title":"Intercensal Estimates of Population of Counties by Age, Sex and Race: 1980-1989","year":"1993"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib55","series-title":"Bridged-race intercensal estimates of the resident population of the United States for July 1, 1990\u2013July 1, 1999, by year, county, single-year of age (0, 1, 2,\u2026, 85 years and over), bridged race, Hispanic origin, and sex","year":"1993"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib56","series-title":"Bridged-race intercensal estimates of the resident population of the United States for July 1, 2000\u2013July 1, 2009, by year, county, single-year of age (0, 1, 2,\u2026, 85 years and over), bridged race, Hispanic origin, and sex","year":"2003"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib57","series-title":"Estimates of the April 1, 2010 resident population of the United States, by county, single-year of age (0, 1, 2,\u2026, 85 years and over), bridged race, Hispanic origin, and sex","year":"2011"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib58","unstructured":"National Center for Health Statistics. Annual estimates of the resident population by sex, single year of age, race, and Hispanic origin for the United States: April 1, 2010 to July 1, 2017.\u00a02018."},{"key":"10.1016\/j.annemergmed.2020.08.009_bib59","series-title":"Applied Regression Analysis and Other Multivariable Methods","author":"Kleinbaum","year":"1998"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib60","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/003335491613100221","article-title":"Defining sickle cell disease mortality using a population-based surveillance system, 2004 through 2008","volume":"131","author":"Paulukonis","year":"2016","journal-title":"Public Health Rep"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib61","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/pbc.24459","article-title":"Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs","volume":"60","author":"Blinder","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib62","first-page":"1","article-title":"Deaths: final data for 2016","volume":"67","author":"Xu","year":"2018","journal-title":"Natl Vital Stat Rep"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib63","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.15374","article-title":"Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease","volume":"2","author":"Lubeck","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib64","doi-asserted-by":"crossref","first-page":"a011783","DOI":"10.1101\/cshperspect.a011783","article-title":"The natural history of sickle cell disease","volume":"3","author":"Serjeant","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib65","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0264-410X(02)00807-1","article-title":"The potential indirect effect of conjugate pneumococcal vaccines","volume":"21","author":"O'Brien","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib66","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1542\/peds.2007-0018","article-title":"Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life","volume":"121","author":"Adamkiewicz","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib67","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1182\/blood-2005-10-009506","article-title":"Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results","volume":"108","author":"Lee","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib68","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jamapediatrics.2013.89","article-title":"Changing ethnic disparity in ischemic stroke mortality in US children after the STOP trial","volume":"167","author":"Lehman","year":"2013","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib69","series-title":"Hydroxyurea for the Treatment of Sickle Cell Disease","author":"Segal","year":"2008"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib70","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ajh.22012","article-title":"Oxidative stress in sickle cell disease: pathophysiology and potential implications for disease management","volume":"86","author":"Nur","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib71","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1067\/mpd.2001.119590","article-title":"A\u00a0two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia","volume":"139","author":"Wang","year":"2001","journal-title":"J\u00a0Pediatr"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib72","series-title":"FDA Approves Hydroxyurea for Treatment of Pediatric Patients With Sickle Cell Anemia","year":"2017"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib73","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ajh.21749","article-title":"Hydroxyurea in children with sickle cell disease: practice patterns and barriers to utilization","volume":"85","author":"Brandow","year":"2010","journal-title":"Am J Hematol"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib74","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1093\/pm\/pnw074","article-title":"The opioid drug epidemic and sickle cell disease: guilt by association","volume":"17","author":"Ruta","year":"2016","journal-title":"Pain Med"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib75","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1136\/bmj.318.7198.1585","article-title":"Experiences of hospital care and treatment seeking for pain from sickle cell disease: qualitative study","volume":"318","author":"Maxwell","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib76","first-page":"1050","article-title":"Health-related stigma in young adults with sickle cell disease","volume":"102","author":"Jenerette","year":"2010","journal-title":"J\u00a0Natl Med Assoc"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib77","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1477-7525-3-50","article-title":"Health related quality of life in sickle cell patients: the PiSCES project","volume":"3","author":"McClish","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.annemergmed.2020.08.009_bib78","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/PSY.0b013e31815ff5c5","article-title":"Depression and anxiety in adults with sickle cell disease: the PiSCES project","volume":"70","author":"Levenson","year":"2008","journal-title":"Psychosom Med"}],"container-title":["Annals of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064420306491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064420306491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T04:43:28Z","timestamp":1759293808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196064420306491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0196064420306491"],"URL":"https:\/\/doi.org\/10.1016\/j.annemergmed.2020.08.009","relation":{},"ISSN":["0196-0644"],"issn-type":[{"value":"0196-0644","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in Sickle Cell Disease\u2013Related Mortality in the United States, 1979 to 2017","name":"articletitle","label":"Article Title"},{"value":"Annals of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annemergmed.2020.08.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American College of Emergency Physicians.","name":"copyright","label":"Copyright"}]}}